{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:43:21Z","timestamp":1793465001763,"version":"4.5.0"},"reference-count":116,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Dermatology Association of Ontario"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Cytokines in the interleukin (IL)\u221223\/IL-17 axis are central to psoriasis pathogenesis. Janus kinase (JAK) signal transducer and activator of transcription (STAT) regulates intracellular signalling of several cytokines (including IL-12, 23, 22, 6, 17, and interferon (IFN)-\u03b3) in the IL-23\/IL-17 axis, and, as a result, has become a therapeutic target for psoriasis treatment. Although several JAK1-3 inhibitors, with varying degrees of selectivity, have been developed for immune-mediated inflammatory diseases, use in psoriasis is limited by a low therapeutic index as anticipated by signals from other disease indications. More selective inhibition of the JAK family is an area of interest. Specifically, selective tyrosine kinase (TYK)2 inhibition suppresses IL-23\/IL-17 axis signalling, and at therapeutic doses, has a favorable safety profile compared to therapeutic doses of JAK1-3 inhibitors. Phase III efficacy and safety data for the selective allosteric TYK2-inhibitor, deucravacitinib, in adult patients with moderate-to-severe plaque psoriasis is promising. Furthermore, phase II clinical trials for ropsacitinib (PF-06826647), a selective TYK2 inhibitor, and brepocitinib (PF-06700841), a JAK1\/TYK2 inhibitor, have also demonstrated efficacy and an acceptable safety profile in adult patients with moderate-to-severe plaque psoriasis. Other novel TYK2 allosteric inhibitors, NDI-034858 and ESK-001, are currently being investigated in adult patients with plaque psoriasis. This article reviews the details of the JAK-STAT pathway in psoriasis pathophysiology, the rationale for selective targeting of JAKs in the treatment of psoriasis, and provides clinical perspective on clinical trial data for JAK and TYK2 inhibitors.<\/jats:p>","DOI":"10.1177\/12034754221141680","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:36:18Z","timestamp":1671086178000},"page":"3S-24S","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway"],"prefix":"10.1177","volume":"27","author":[{"given":"Wei Jing","family":"Loo","sequence":"first","affiliation":[{"name":"DermEffects, London, Ontario, Canada"},{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-9050","authenticated-orcid":false,"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Brunswick Dermatology Center, Fredericton, NB, Canada"},{"name":"Department of Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada"},{"name":"Section of Community Pediatrics, Department of Pediatrics, Calgary, AB, Canada"},{"name":"Section of Pediatric Rheumatology, Department of Pediatrics, Calgary, AB, Canada"},{"name":"Skin Health & Wellness Centre, Calgary, AB, Canada"},{"name":"Dermatology Research Institute, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"SKiN Centre for Dermatology, Peterborough, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parbeer","family":"Grewal","sequence":"additional","affiliation":[{"name":"Rejuvenation Dermatology, Edmonton, AB, Canada"},{"name":"Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada"},{"name":"Dr. Chih-Ho Hong Medical Inc., Surrey, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-3844","authenticated-orcid":false,"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ronald B.","family":"Vender","sequence":"additional","affiliation":[{"name":"Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada"},{"name":"Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc, Montreal, QC, Canada"},{"name":"Department of Medicine, Division of Dermatology, Montreal University Hospital Center, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"K Papp Clinical Research, Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"bibr1-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663"},{"key":"bibr2-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00518-8"},{"key":"bibr3-12034754221141680","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2009.08068"},{"key":"bibr4-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.008"},{"key":"bibr5-12034754221141680","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"bibr6-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00085.x"},{"key":"bibr7-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1988.01670070040016"},{"issue":"3","key":"bibr8-12034754221141680","first-page":"280","volume":"137","author":"Krueger G.","year":"2001","journal-title":"Arch Dermatol"},{"key":"bibr9-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"bibr10-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.036"},{"key":"bibr11-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"bibr12-12034754221141680","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735"},{"key":"bibr13-12034754221141680","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5699"},{"key":"bibr14-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8"},{"key":"bibr15-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605"},{"key":"bibr16-12034754221141680","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202859"},{"key":"bibr17-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"bibr18-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/366583a0"},{"key":"bibr19-12034754221141680","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401867"},{"key":"bibr20-12034754221141680","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00287"},{"issue":"9","key":"bibr21-12034754221141680","first-page":"1329","volume":"5","author":"Firmbach-Kraft I.","year":"1990","journal-title":"Oncogene"},{"issue":"7","key":"bibr22-12034754221141680","first-page":"1347","volume":"7","author":"Harpur AG.","year":"1992","journal-title":"Oncogene"},{"issue":"4","key":"bibr23-12034754221141680","first-page":"2057","volume":"11","author":"Wilks AF.","year":"1991","journal-title":"Mol Cell Biol"},{"key":"bibr24-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6374"},{"key":"bibr25-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2099"},{"key":"bibr26-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.672048"},{"key":"bibr27-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"bibr28-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"bibr29-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.07.008"},{"key":"bibr30-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15382"},{"key":"bibr31-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1974"},{"key":"bibr32-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/nm1162"},{"key":"bibr33-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12049"},{"issue":"5","key":"bibr34-12034754221141680","first-page":"S2","volume":"33","author":"Alwan W.","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"bibr35-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"issue":"5","key":"bibr36-12034754221141680","first-page":"1092","volume":"159","author":"Nograles KE.","year":"2008","journal-title":"Br J Dermatol"},{"key":"bibr37-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.09.002"},{"key":"bibr38-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b21-00609"},{"key":"bibr39-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5RU0519-145R"},{"key":"bibr40-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1002\/art.41906"},{"key":"bibr41-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"bibr42-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"bibr43-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"bibr44-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"bibr45-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"bibr46-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895"},{"key":"bibr47-12034754221141680","unstructured":"Galapagos NV.\n                      Jyselca: Summary of Product Characteristics\n                      . European Medicines Agency; 2020:47. Updated May 3, 2022. Accessed June 5, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf"},{"key":"bibr48-12034754221141680","unstructured":"AbbVie Corporation.\n                      Rinvoq Product Monograph\n                      2019 69. Updated Aug 02, 2022. Accessed August 08, 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00066875.PDF"},{"key":"bibr49-12034754221141680","unstructured":"Pfizer Canada ULC.\n                      Cibinqo Product Monograph\n                      2022:37. Updated June 28, 2022. Accessed July 5, 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00066473.PDF"},{"key":"bibr50-12034754221141680","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.supp.37"},{"key":"bibr51-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"bibr52-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"bibr53-12034754221141680","doi-asserted-by":"publisher","DOI":"10.2174\/156802612800672844"},{"key":"bibr54-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"bibr55-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"bibr56-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"bibr57-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"bibr58-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"bibr59-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"key":"bibr60-12034754221141680","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. U.S. Food and Drug Administration. 2021. Accessed March 23, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"bibr61-12034754221141680","unstructured":"Health Canada. Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer. Updated Jan 12, 2022. Accessed March 23, 2022. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/health-canada-safety-review-finds-link-between-use-xeljanz-and-xeljanz-xr-tofacitinib"},{"key":"bibr62-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"bibr63-12034754221141680","unstructured":"Pfizer Canada ULC.\n                      Xeljanz Product Monograph\n                      2014 85. Updated Many 09, 2022. Accessed May 15, 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00065725.PDF"},{"key":"bibr64-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"bibr65-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"bibr66-12034754221141680","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"bibr67-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"bibr68-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838"},{"key":"bibr69-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00305-z"},{"key":"bibr70-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"bibr71-12034754221141680","author":"Armstrong AW.","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"bibr72-12034754221141680","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.supp.4"},{"key":"bibr73-12034754221141680","doi-asserted-by":"crossref","unstructured":"Armstrong A., Warren RB., Sofen H et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials. presented at: American Academy of Dermatology Annual Meeting; 2022; Boston. https:\/\/aad-eposters.s3.amazonaws.com\/AM2022\/poster\/34658\/Deucravacitinib+an+Oral+Selective+Tyrosine+Kinase+2+TYK2+Inhibitor+in+Patients+With+Moderate+to+Severe+Plaque+Psoriasis+Who+Had+Inadequate+Responses+to+Apremilast+at+Week+24+in+the+Phase+3+POETYK+PSO-1+and+PSO-2+Trials.pdf","DOI":"10.1016\/j.jaad.2022.06.657"},{"key":"bibr74-12034754221141680","doi-asserted-by":"crossref","unstructured":"Armstrong AW., Warren RB., Sofen H et al. Deucravacitinib, an oral, selective tyrosine Kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials. presented at: Annual Meeting of the American Academy of Dermatology; 2022; Boston, MA. https:\/\/aad-eposters.s3.amazonaws.com\/AM2022\/poster\/34658\/Deucravacitinib+an+Oral+Selective+Tyrosine+Kinase+2+TYK2+Inhibitor+in+Patients+With+Moderate+to+Severe+Plaque+Psoriasis+Who+Had+Inadequate+Responses+to+Apremilast+at+Week+24+in+the+Phase+3+POETYK+PSO-1+and+PSO-2+Trials.pdf","DOI":"10.1016\/j.jaad.2022.06.657"},{"key":"bibr75-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.197"},{"key":"bibr76-12034754221141680","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.supp.48"},{"key":"bibr77-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.03.962"},{"key":"bibr78-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059"},{"key":"bibr79-12034754221141680","unstructured":"Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus. June 28, 2022. Accessed August 5, 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing"},{"key":"bibr80-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.590"},{"key":"bibr81-12034754221141680","unstructured":"Alumis Inc. Multiple dose study to determine safety and tolerability of ESK-001 in healthy participants. Accessed October 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05431634?term=ESK-001&draw=2&rank=1"},{"key":"bibr82-12034754221141680","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0096"},{"key":"bibr83-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00333-w"},{"key":"bibr84-12034754221141680","unstructured":"Pfizer.\n                      Cibinqo Highlights of Prescribing Information\n                      2022:31. Accessed June 8, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf"},{"key":"bibr85-12034754221141680","unstructured":"European Medicines Agency.\n                      Cibinqo-Product Information\n                      . 2021:47. Accessed July 12, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf"},{"key":"bibr86-12034754221141680","unstructured":"Eli Lilly Canada Inc.\n                      Olumiant Product Monograph\n                      2020. Accessed April 9. https:\/\/pi.lilly.com\/ca\/olumiant-ca-pm.pdf"},{"key":"bibr87-12034754221141680","unstructured":"European Medicines Agency. Olumiant (baricitinib): An overview of Olumiant and why it is authorised in the EU. Accessed May 15, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/olumiant-epar-medicine-overview_en.pdf"},{"key":"bibr88-12034754221141680","unstructured":"Eli Lillly and Company.\n                      Olumiant Highlights of Prescribing Information\n                      . 2018. Accessed May 25, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924Orig1s000lbl.pdf"},{"key":"bibr89-12034754221141680","unstructured":"FDA Approves First Systemic Treatment for Alopecia Areata. June 13, 2022. Accessed July 14, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-systemic-treatment-alopecia-areata"},{"key":"bibr90-12034754221141680","unstructured":"Eli Lillly and Company.\n                      Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitnib\n                      2022:14. Updated May 2022. Accessed July 14, 2022. https:\/\/www.fda.gov\/media\/143823\/download"},{"key":"bibr91-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"bibr92-12034754221141680","unstructured":"Product Information - Sotyktu. 2022-11-24. https:\/\/health-products.canada.ca\/dpd-bdpp\/dispatch-repartition.do"},{"key":"bibr93-12034754221141680","unstructured":". Bristol-Myers Squibb Company. Highlights of Prescribing Informati0n - Sotyktu (Deucravacitinib). 09-2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214958s000lbl.pdf"},{"key":"bibr94-12034754221141680","unstructured":"European Medicines Agency. Jyseleca (filgotinib): An overview of Jyseleca and why it is authorised in the EU. Updated 2021. Accessed June 5 2022. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/jyseleca-epar-medicine-overview_en.pdf"},{"key":"bibr95-12034754221141680","unstructured":"Jyseleca\u00ae (Filgotinib) Approved in Japan for Rheumatoid Arthritis. GIlead. September 25, 2020. Accessed July 05, 2022. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/9\/jyseleca-filgotinib-approved-in-japan-for-rheumatoid-arthritis"},{"key":"bibr96-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13745"},{"key":"bibr97-12034754221141680","unstructured":"Novartis Pharmaceuticals Canada Inc.\n                      Jakavi Product Monograph\n                      2012:75. Updated Jun 08, 2022. Accessed June 15,2022. https:\/\/pdf.hres.ca\/dpd_pm\/00066253.PDF"},{"key":"bibr98-12034754221141680","unstructured":"European Medicines Agency.\n                      Jakavi (ruxolitinib): An overview of Jakavi and why it is authorised in the EU\n                      . 2022. Updated April 2022. Accessed June 8, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/jakavi-epar-summary-public_en.pdf"},{"key":"bibr99-12034754221141680","unstructured":"Incyte Corportation. Jakafi highlights of prescribing information. 2011;23."},{"key":"bibr100-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14399"},{"key":"bibr101-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00627-2"},{"key":"bibr102-12034754221141680","unstructured":"European Medicines Agency.\n                      Xeljanz Summary of Product Characteristics\n                      2017 170. Updated May 24, 2022. Accessed June 7, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf"},{"key":"bibr103-12034754221141680","unstructured":"Pfizer.\n                      Xeljanz Highlights of Prescribing Information\n                      . 2012:33. Accessed June 16, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203214s000lbl.pdf"},{"key":"bibr104-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000819"},{"key":"bibr105-12034754221141680","unstructured":"European Medicines Agency. Rinvoq (upadacitinib). Accessed May 4 2022. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rinvoq-epar-medicine-overview_en-0.pdf"},{"key":"bibr106-12034754221141680","unstructured":"AbbVie Inc.\n                      Rinvoq Highlights of Prescribing Information\n                      2019 31. Updated August 2019. Accessed June 9, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf"},{"key":"bibr107-12034754221141680","unstructured":"Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735. June 29, 2022, 2022. Accessed August 08, 2022. https:\/\/ir.ventyxbio.com\/node\/7066\/pdf"},{"key":"bibr108-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01291-2"},{"key":"bibr109-12034754221141680","unstructured":"Incyte Corportation.\n                      Opzelura Highlights of Prescribing Information\n                      2011:22. Updated July 2022. Accessed May 24, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215309s001lbl.pdf"},{"key":"bibr110-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"bibr111-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"bibr112-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"bibr113-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00410-z"},{"key":"bibr114-12034754221141680","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"bibr115-12034754221141680","doi-asserted-by":"crossref","unstructured":"Lebwohl M., Gooderham M., Warren RB et al. Deucravacitinib, an oral, selective Tyrosine Kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials. presented at: American Academy of Dermatology Annual Meeting; 2022; Boston. https:\/\/aad-eposters.s3.amazonaws.com\/AM2022\/poster\/34660\/Deucravacitinib+an+Oral+Selective+Tyrosine+Kinase+2+TYK2+Inhibitor+Versus+Placebo+and+Apremilast+in+Moderate+to+Severe+Plaque+Psoriasis+Achievement+of+Absolute+PASI+Thresholds+in+the+Phase+3+POETYK+PSO-1+and+PSO-2+Trials.pdf","DOI":"10.1016\/j.jaad.2022.06.199"},{"key":"bibr116-12034754221141680","unstructured":"Warren RB et al. Oral presentation-deucravacitinib, an oral, selective Tyrosine Kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and PSO-2 trials. presented at: EADV Annual Meeting September 20, 2021 2021; Session FC03.06."}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754221141680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754221141680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754221141680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:49:35Z","timestamp":1777391375000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754221141680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":116,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/12034754221141680"],"URL":"https:\/\/doi.org\/10.1177\/12034754221141680","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}